Non Invasive Neuromodulation Once Seen As "Futuristic" Now Seen Offering Effective Treat Ment For Acute Pain; Electromedical Technologies, Inc.'S (Otcqb: Emed) Devices Of Fer Relief For Patients With Chronic And Acute Pain

The medical community is seeking to deliver acute pain and chronic pain management in numerous ways. Most recently, a medical review of 'neuromodulation' said the treatment was once seen as only "futuristic' in a new review of the technique in Practical Pain Management Magazine. The review said the technique is now delivering "impressive resiliency and versatility" in treating pain issues. Some providers may have at first been skeptical, but the devices provided pain relief to all patients who have trialed it -- especially patients suffering from chronic pain and the complex regional pain syndrome (RPS).

The chronic pain treatment market has drawn intense interest from media companies. stockmarketpress.com features specialized coverage of related stocks such as Electromedical Technologies, Inc. (OTCQB: EMED), Medtronic PLC (NYSE: MDT), Nevro Corp. (NYSE: NVRO), Axsome Therapeutics, Inc. (NASDAQ: AXSM). GlaxoSmithKline (NYSE: GSK), Abbott Laboratories (NYSE: TBA), Eli Lilly (NYSE: LLY), Boston Scientific Corporation (NYSE: BSX), Novartis AG (NYSE: NVS), Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb (NYSE: BMY).

Non-Invasive Neuromodulation Once Seen As "Futuristic" Now Seen Offering Effective Treatment For Acute Pain; Electromedical Technologies, Inc.'s (OTCQB: EMED) Devices Offer Relief For Patients With Chronic And Acute Pain

Electromedical Technologies, Inc.'s (OTCQB: EMED) Devices Offer Relief For Patients With Chronic And Acute Pain Non-Invasive Neuromodulation Once Seen As "Futuristic" Now Seen Offering Effective Treatment For Acute Pain; Electromedical Technologies, Inc.'s (OTCQB: EMED) Devices Offer Relief For Patients With Chronic And Acute Pain.

Telemedicine devices and products like Electromedical Technologies, Inc.'s (OTCQB: EMED) FDA cleared and non-invasive line of WellnessPro Plus(TM) products are in demand, especially when the COVID-19 pandemic hampers regular visits to medical teams to home-bound patients. Home devices that can offer relief to acute and chronic pain are in demand.

COVID-19 Pandemic Drives Innovative Need For More Telemedicine And Remote Control Devices

Electromedical Technologies, Inc. (OTCQB: EMED) focuses on how to relieve chronic and acute pain with non-invasive devices which do have addictive pain killer drugs which may have the side effect of addiction to opioids. It saves overworked medical staffs from dealing with even more complications from acute pain. EMED's WellnessPro Plus(TM) device plays a critical role in delivering pain relief, not being invasive and treating patients without addictive pain killer prescription pharmaceuticals. Non-Invasive Neuromodulation Once Seen As "Futuristic" Now Seen Offering Effective Treatment For Acute Pain; Electromedical Technologies, Inc.'s (OTCQB: EMED) Devices Offer Relief For Patients With Chronic And Acute Pain.

The Best Is Yet To Come: The WellnessPlus POD Portal That Offers Remote Real Time Monitoring Of Treatment

Electromedical Technologies, Inc. (OTCQB: EMED) in the near future -- late 2021 -- plans to offer physicians, providers and trained technicians the smaller and feature-intensive WellnessPlus POD. A smaller and less costly device, the POD model offers staff a special feature: a portal that enables supervising staff the ability to monitor in real time how a patient is receiving pain relief from the device. In a time of home-bound pandemic suffering patients, this is an important new feature.

Anticipating More Onboard Medical Practitioners And Distributors, EMED Invests In More Year-End Inventory

Already, Electromedical Technologies, Inc. (OTCQB: EMED) Has Built More WellnessPro Plus(TM) device inventory for an anticipated accelerated demand in 2021 for the product. As an alternative to opioid-addicting pharmaceuticals, the device solves acute and chronic pain for patients. Non-Invasive Neuromodulation Once Seen As "Futuristic" Now Seen Offering Effective Treatment For Acute Pain; Electromedical Technologies, Inc.'s (OTCQB: EMED) Devices Offer Relief For Patients With Chronic And Acute Pain.

Goldman Small Cap Research Report Projects EMED Will Reach $17 Million By 2022

A new Goldman Small Cap Research report projects EMED conservatively to reach $17 million in volume by 2022, and perhaps as high as $22 million with unit sales of its devices that year reaching 80,000 or 90,000 units. Goldman Small Cap Research projected EMED's FDA cleared WellnessPro Plus device will exponentially grow in sales.

The analysis is especially bullish about the sales of the to-be-introduced in late 2021 after an anticipated FDA clearance of the WellnessPlus POD, which features a remote monitoring portal. The telemedicine-like remote portal will enable physicians and technicians to monitor in real time a remote view of therapy effectiveness -- a trend as medical facilities are stressed due to COVID-19. The FDA has just issued emergency use authorizations for remote devices.

Remote Control Treatment Monitoring Trending In Medical Field

Certain remote or patient-wearing monitoring devices may enable physicians and caretakers to operate a medical device from a non co-located space with the patient. The strain of COVID-19 requires medical innovation and remote monitoring. Electromedical Technologies, Inc.'s (OTCQB: EMED) WellnessPlus POD with remote monitoring portal could be a vital device for hard-pressed medical staffs inundated pandemic patent levels.

Telemedicine Devices In Demand During Spike In COVID-19 Patients

In medical fields, the use of remote monitoring devices enables medical facilities to provide treatments for in-house patients as well as real time monitoring by medical providers.

Projected Volume For EMED In 2022 Could Be $17-$22 Million: Goldman Report

The Goldman report projects that Electromedical Technologies, Inc. (OTCQB: EMED) could sell up to 80,000-90,000 units in 2022 with a premium portal feature that could provide remote monitoring of patient treatment and drive 2022 volume as high as $22 million. Goldman Small Cap Research last week set a $5.70 12-Month Price Target For Electromedical Technologies, Inc. (OTCQB: EMED), in an Opportunity Research report.

Medical institutions are looking to alternative therapies to relieve chronic and acute pain that do not contain prescription drugs, which have the side effect of addiction to opioids.

Remote Monitoring Portal Feature In POD Model Is Seen Driving Sales

The company has a combination purchase down payment/subscription payment revenue model which provides recurring revenue for sales of its devices. The upbeat forecast by Goldman SmallCap Research is largely based on prior sales of the FDA cleared Wellness Pro Plus. Analyst Rob Goldman wrote that he was especially impressed with its telemedicine-like portal feature that permits physicians or technicians to monitor in real time and from a remote location how the wearable POD therapy will deliver relief from acute and chronic pain.

EMED Offers Devices Which Are Alternative To Opioid Addicting Pain Killer Drugs

Electromedical Technologies, Inc. (OTCQB: EMED has successfully marketed its non-invasive FDA-cleared WellnessPro Plus(TM) as an alternative treatment to opioid pain killer pharmaceuticals, which can be addictive. As a result, Matthew Wolfson, CEO, believes that patients who have experienced chronic pain relief from the bioelectronics and electro-modulation delivered by the Wellness Pro Plus devices warrant the investment in the year-end inventory build-up. In anticipation of a rush for the product in early 2021, the company has invested $4.2 Million as it has built and paid for a 1,200+ unit inventory in preparation for attracting hundreds more medical practitioners and distributors in 2021.

The WellnessPlus Pod Seen Debuting In Late 2021, After Anticipated FDA Clearance

Electromedical Technologies, Inc. (OTCQB: EMED) will debut in late 2021 the WellnessPlus POD a device that features a special portal for telemedicine-like real time monitoring by physicians. The WellnessPro POD links doctors/technicians and patients with that feature and is less costly, smaller, portable and offers a remote POD portal. The device also provides a unique financial sales structure for the Company, combining a down payment purchase with a recurring monthly subscription services fee.

Source: Stock Market Press

Join Stock Market Press' newsletter for the latest in IPO, market commentary and company profiles.

Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.

Contact:

Stock Market Press
110 Wall St.
New York, NY 10005 info@stockmarketpress.com Safe Harbor Statement:

Statements in this news release may be "forward-looking statements." Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.

See Stock Market Press disclaimer: http://stockmarketpress.com/disclaimer/ SOURCE: Stock Market Press

comtex tracking

COMTEX_375738654/2718/2020-12-08T07:09:19

Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.